In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite.
An ultrafiltration technique or equilibrium dialysis has been used to study the in vitro human plasma protein binding of racemic zileuton, its individual enantiomers, and its pharmacologically inactive metabolite N-dehydroxyzileuton. The plasma protein binding of zileuton and N-dehydroxyzileuton over the concentration range of 0.1 to 100 mg/L averaged 93.1 +/- 0.22 and 92.0 +/- 0.12%, respectively. However, there appeared to be a stereoselective effect, with the R(+) enantiomer of zileuton demonstrating greater binding to plasma proteins than the S(-) enantiomer (96 vs 88%, respectively). Zileuton was bound to both human serum albumin (40 g/L) and alpha 1-acid glycoprotein (1 g/L), although binding affinity to albumin was approximately 3-fold greater. Displacement interactions of zileuton with warfarin, salicylate, theophylline, naproxen, ibuprofen, prednisone, and terfenadine were minimal. The blood to plasma concentration ratio for zileuton and N-dehydroxyzileuton ranged from 0.65 to 0.68, indicating that these compounds were mainly distributed in the plasma. Thus, zileuton is approximately 93% bound to plasma proteins at expected therapeutic concentrations in vitro, and this figure is largely unaffected by several commonly prescribed agents with which the drug may be coadministered.
Machinist
J M
JM
Biotransformation Department, Abbott Laboratories, Abbott Park, Illinois, USA.
Kukulka
M J
MJ
Bopp
B A
BA
D000328:Adult; D018926:Anti-Allergic Agents / Q000097:blood / Q000494:pharmacology; D000893:Anti-Inflammatory Agents / Q000097:blood / Q000494:pharmacology; D000925:Anticoagulants / Q000097:blood / Q000494:pharmacology; D001798:Blood Proteins / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D004347:Drug Interactions; D005260:Female; D006400:Hematocrit; D006801:Humans; D006900:Hydroxylation; D006918:Hydroxyurea / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D007052:Ibuprofen / Q000097:blood / Q000494:pharmacology; D066298:In Vitro Techniques; D007553:Isotope Labeling; D016859:Lipoxygenase Inhibitors / Q000097:blood* / Q000493:pharmacokinetics; D008297:Male; D009288:Naproxen / Q000097:blood / Q000494:pharmacology; D011239:Prednisolone / Q000097:blood / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects; D012459:Salicylates / Q000097:blood / Q000494:pharmacology; D013237:Stereoisomerism; D016593:Terfenadine / Q000097:blood / Q000494:pharmacology; D013806:Theophylline / Q000097:blood / Q000494:pharmacology; D014859:Warfarin / Q000097:blood
D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D001798:Blood Proteins; D016859:Lipoxygenase Inhibitors; D012459:Salicylates; D009288:Naproxen; D014859:Warfarin; D016593:Terfenadine; D011239:Prednisolone; D013806:Theophylline; C063449:zileuton; D007052:Ibuprofen; D006918:Hydroxyurea